Aplagon Oy

Aplagon is an early clinical-stage biopharmaceutical company developing first-in-class therapeutic solutions for severe cardiovascular/kidney diseases.  Our product APAC uniquely targets the vascular injury sites and cools down thrombo-inflammatory processes, key underlying drivers in many cardiovascular/kidney diseases. Our first target indications are hemodialysis access failure (local administration) and advanced peripheral arterial occlusive disease (PAOD) / chronic kidney disease (CKD) (systemic administration). We have recently secured up to $9 million in EIC funding (grant and matching equity funding) for our clinical programs and received promising early data from our ongoing hemodialysis access failure (AVF-maturation failure) clinical study.